Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07567469
NCT07567469Not yet recruitingPhase 1

A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) and Cemiplimab Alone Followed by Adjuvant Fianlimab in Combination With Cemiplimab in Pediatric and Young Adult Participants With Recurrent or Progressive High-Grade Glioma or Pediatric and Adult Participants With Recurrent or Progressive Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals0 sites120 target enrollmentStarted: August 31, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Enrollment
120
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. "Recurrent" means that the cancer came back after treatment. "Progressive" means that the tumor has grown or spread.

The aim of the study is to see how safe, tolerable, and effective cemiplimab and the combination of fianlimab and cemiplimab are.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drug(s)
  • Do the study drug(s) help study participants live longer without their tumors growing or spreading
  • How much of the study drug(s) is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the study drug[s] less effective or lead to side effects)

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
0 Years to 39 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Participant must be diagnosed with recurrent/progressive HGG or PF-A ependymoma with unequivocal progression on Magnetic Resonance Imaging (MRI) as described in the protocol
  • •Participant must have histologically confirmed (at initial diagnosis or relapse) HGG or PF-A ependymoma
  • •Participant must be an adequate medical candidate for surgical resection as described in the protocol
  • •Karnofsky Performance Status (KPS) score ≥50 (in participants ≥16 years) or Lansky Performance Status (LPS) score ≥50 (in participants <16 years) as described in the protocol
  • •Adequate organ function as described in the protocol

Exclusion Criteria

  • •Active autoimmune disease requiring systemic immunosuppressive therapy in the past 2 years
  • •Active, serious medical illness, infection or other systemic illness which would limit participation in the trial
  • •Has not yet recovered from any acute toxicities resulting from prior therapy
  • •History of myocarditis
  • •Prior treatment with antibodies to Programmed Cell Death Protein -1 (PD-1), Programmed Cell Death Protein Ligand -1 (PD-L1), Lymphocyte Activation Gene 3 (LAG3), or Cytotoxic T-Lymphocyte Associated protein 4 (CTLA-4)
  • •Treatment with high dose systemic corticosteroids as described in the protocol
  • •History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management
  • •Note: Other protocol defined Inclusion/ Exclusion Criteria apply

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Recruiting
Phase 2
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma.
2025-520698-38-00Instituto Oncologico Dr. Rosell S.L.18
Recruiting
Phase 2
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)
2024-512652-38-00Replimune Group Inc.143
Recruiting
Phase 2
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
NCT07433673Columbia University20
Recruiting
Phase 2
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialGlioblastoma
NCT07263438Centre Hospitalier Universitaire Vaudois59
Not yet recruiting
Phase 2
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and NeckSquamous Cell Carcinoma
NCT07346196University of Chicago90